Literature DB >> 24118922

Targeting p53 in melanoma.

Neil F Box1, Tyler O Vukmer, Tamara Terzian.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24118922      PMCID： PMC4112749          DOI： 10.1111/pcmr.12180

Source DB:  PubMed          Journal:  Pigment Cell Melanoma Res        ISSN： 1755-1471            Impact factor:   4.693


× No keyword cloud information.
  5 in total

1.  A landscape of driver mutations in melanoma.

Authors:  Eran Hodis; Ian R Watson; Gregory V Kryukov; Stefan T Arold; Marcin Imielinski; Jean-Philippe Theurillat; Elizabeth Nickerson; Daniel Auclair; Liren Li; Chelsea Place; Daniel Dicara; Alex H Ramos; Michael S Lawrence; Kristian Cibulskis; Andrey Sivachenko; Douglas Voet; Gordon Saksena; Nicolas Stransky; Robert C Onofrio; Wendy Winckler; Kristin Ardlie; Nikhil Wagle; Jennifer Wargo; Kelly Chong; Donald L Morton; Katherine Stemke-Hale; Guo Chen; Michael Noble; Matthew Meyerson; John E Ladbury; Michael A Davies; Jeffrey E Gershenwald; Stephan N Wagner; Dave S B Hoon; Dirk Schadendorf; Eric S Lander; Stacey B Gabriel; Gad Getz; Levi A Garraway; Lynda Chin
Journal:  Cell       Date:  2012-07-20       Impact factor: 41.582

2.  p53 prevents progression of nevi to melanoma predominantly through cell cycle regulation.

Authors:  Tamara Terzian; Enrique C Torchia; Daisy Dai; Steven E Robinson; Kazutoshi Murao; Regan A Stiegmann; Victoria Gonzalez; Glen M Boyle; Marianne B Powell; Pamela M Pollock; Guillermina Lozano; William A Robinson; Dennis R Roop; Neil F Box
Journal:  Pigment Cell Melanoma Res       Date:  2010-12       Impact factor: 4.693

Review 3.  Ultraviolet radiation and melanoma: a systematic review and analysis of reported sequence variants.

Authors:  Thomas Hocker; Hensin Tsao
Journal:  Hum Mutat       Date:  2007-06       Impact factor: 4.878

4.  MDM4 is a key therapeutic target in cutaneous melanoma.

Authors:  Agnieszka Gembarska; Flavie Luciani; Clare Fedele; Elisabeth A Russell; Michael Dewaele; Stéphanie Villar; Aleksandra Zwolinska; Sue Haupt; Job de Lange; Dana Yip; James Goydos; Jody J Haigh; Ygal Haupt; Lionel Larue; Aart Jochemsen; Hubing Shi; Gatien Moriceau; Roger S Lo; Ghanem Ghanem; Mark Shackleton; Federico Bernal; Jean-Christophe Marine
Journal:  Nat Med       Date:  2012-07-22       Impact factor: 53.440

5.  A melanoma molecular disease model.

Authors:  Smruti J Vidwans; Keith T Flaherty; David E Fisher; Jay M Tenenbaum; Michael D Travers; Jeff Shrager
Journal:  PLoS One       Date:  2011-03-30       Impact factor: 3.240
  5 in total
  15 in total

1.  Melanoma vaccines: clinical status and immune endpoints.

Authors:  Deena M Maurer; Lisa H Butterfield; Lazar Vujanovic
Journal:  Melanoma Res       Date:  2019-04       Impact factor: 3.599

2.  Combining p53 stabilizers with metformin induces synergistic apoptosis through regulation of energy metabolism in castration-resistant prostate cancer.

Authors:  Long Chen; Nihal Ahmad; Xiaoqi Liu
Journal:  Cell Cycle       Date:  2016       Impact factor: 4.534

3.  Transcriptome stability profiling using 5'-bromouridine IP chase (BRIC-seq) identifies novel and functional microRNA targets in human melanoma cells.

Authors:  Piyush Joshi; Tatsuya Seki; Shinobu Kitamura; Andrea Bergano; Bongyong Lee; Ranjan J Perera
Journal:  RNA Biol       Date:  2019-06-16       Impact factor: 4.652

4.  AXL receptor signalling suppresses p53 in melanoma through stabilization of the MDMX-MDM2 complex.

Authors:  Anna de Polo; Zhongling Luo; Casimiro Gerarduzzi; Xiang Chen; John B Little; Zhi-Min Yuan
Journal:  J Mol Cell Biol       Date:  2017-04-01       Impact factor: 6.216

5.  Management of conjunctival malignant melanoma: a review and update.

Authors:  James R Wong; Afshan A Nanji; Anat Galor; Carol L Karp
Journal:  Expert Rev Ophthalmol       Date:  2014-06

6.  WT1 shRNA delivery using transferrin-conjugated PEG liposomes in an in vivo model of melanoma.

Authors:  Santiago Saavedra-Alonso; Pablo Zapata-Benavides; Ana Karina Chavez-Escamilla; Edgar Manilla-Muñoz; Diana Elisa Zamora-Avila; Moisés Armides Franco-Molina; Cristina Rodriguez-Padilla
Journal:  Exp Ther Med       Date:  2016-10-27       Impact factor: 2.447

7.  MicroRNA-3151 inactivates TP53 in BRAF-mutated human malignancies.

Authors:  Malori A Lankenau; Ravi Patel; Sandya Liyanarachchi; Sophia E Maharry; Kevin W Hoag; Megan Duggan; Christopher J Walker; Joseph Markowitz; William E Carson; Ann-Kathrin Eisfeld; Albert de la Chapelle
Journal:  Proc Natl Acad Sci U S A       Date:  2015-11-18       Impact factor: 11.205

8.  Combined inhibition of the cell cycle related proteins Wee1 and Chk1/2 induces synergistic anti-cancer effect in melanoma.

Authors:  Gry Irene Magnussen; Elisabeth Emilsen; Karianne Giller Fleten; Birgit Engesæter; Viola Nähse-Kumpf; Roar Fjær; Ana Slipicevic; Vivi Ann Flørenes
Journal:  BMC Cancer       Date:  2015-06-10       Impact factor: 4.430

9.  Vitamin D and its low calcemic analogs modulate the anticancer properties of cisplatin and dacarbazine in the human melanoma A375 cell line.

Authors:  Anna Piotrowska; Justyna Wierzbicka; Agnieszka Rybarczyk; Robert C Tuckey; Andrzej T Slominski; Michał A Żmijewski
Journal:  Int J Oncol       Date:  2019-02-25       Impact factor: 5.650

10.  A carbazole compound, 9-ethyl-9H-carbazole-3-carbaldehyde, plays an antitumor function through reactivation of the p53 pathway in human melanoma cells.

Authors:  Jie Wen; Wenqian Chen; Baoxiang Zhao; Qiuping Xu; Chang Liu; Qun Zhang; Zhiwei Xie; Yonggan Yan; Jing Guo; Jun Huang; Junying Miao; Xunwei Wu
Journal:  Cell Death Dis       Date:  2021-06-08       Impact factor: 8.469
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.